Results 31 to 40 of about 124,093 (287)

Phosphodiesterase-5 inhibitors tadalafil and sildenafil potentiate nitrergic-nerve mediated relaxations in the bladder vasculature [PDF]

, 2023
Recent studies suggest that lower urinary tract dysfunction may arise due to changes in local perfusion. Phosphodiesterase-5 inhibitors can improve urinary bladder blood flow, although the local mechanisms have not been fully elucidated.
Nilsson, Damian, Sellers, Donna, Chess-Williams, Russ   +2 more
core   +1 more source

Therapeutic benefits of Phosphodiesterase type 5 inhibitors: A comprehensive review [PDF]

Archives of Pharmaceutical Sciences Ain Shams University
Phosphodiesterase type 5 (PDE5) inhibitors have been widely used to treat erectile dysfunction. This review aims to explore the favorable effects of PDE5 inhibitors in clinical applications beyond their conventional use.
Yasmin Nabil, Yara M. Aboelmagd, Christine Nathan Habib, ٍamar S. Azab   +3 more
doaj   +1 more source

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. [PDF]

, 2017
Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension.
Moynihan, B, Mathilde MH Pauls, Kruuse, C, Christina Kruuse, Isaacs, Jeremy D, Hainsworth, AH, Jeremy B Madigan, Jeremy D Isaacs, Madigan, Jeremy B, Hainsworth, Atticus H, Thomas R Barrick, Atticus H Hainsworth, Madigan, JB, Barry Moynihan, Barrick, TR, Barrick, Thomas R, Pauls, MM, Pauls, Mathilde Mh, Isaacs, JD, Moynihan, Barry, Kruuse, Christina   +20 more
core   +1 more source

Multi-target Natural and Nature-Inspired Compounds against Neurodegeneration: A Focus on Dual Cholinesterase and Phosphodiesterase Inhibitors

Applied Sciences, 2021
Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease.
Giovanni Ribaudo, Maurizio Memo, Alessandra Gianoncelli   +2 more
doaj   +1 more source

Evolution of Phosphodiesterase-5 Inhibitors

The World Journal of Men's Health, 2015
After the launch of sildenafil citrate (Viagra®), the last great invention of the 20th century, in 1998, oral phosphodiesterase (PDE)-5 inhibitors were established as first-line treatment for erectile dysfunction (ED), representing a paradigm shift in the diagnosis and treatment of ED [1].
openaire   +2 more sources

Pharmacotherapy of erectile dysfunction: Current standards

Indian Journal of Urology, 2006
Pharmacotherapy is currently the therapeutic option of choice for erectile dysfunction. Comprising mainly intracavernosal injection therapy using alprostadil or alprostadil combined with phentolamine and/or papaverine and oral phosphodiesterase-5 ...
Kew-Kim Chew
doaj   +1 more source

Antioxidant effects of phosphodiesterase-5 inhibitors [PDF]

Cardiovascular Research, 2013
This letter refers to ‘The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension’ by Y.-F. Fan et al ., Cardiovascular Research (2013) 99, 395–403. Fan et al .1 have shown convincing results indicating that the phosphodiesterase-5 (PDE5) inhibitor vardenafil reduces oxidative stress and this
openaire   +2 more sources

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry

Arthritis Care &Research, EarlyView.
Objective Mycophenolate mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon because of the lower fibrotic burden and the predominance of vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis, Gerlando Natalello, Rossella De Angelis, Lucrezia Verardi, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Silvia Bellando‐Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Maria Ilenia De Andres, Alessandro Giollo, Cosimo Bruni, Martina Orlandi, Marco Fornaro, Marta Saracco, Cecilia Agnes, Pier Giacomo Cerasuolo, Gabriella Alonzi, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria‐Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Fabrizio Conti, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Maria Antonietta D'Agostino, Clodoveo Ferri, Marco Matucci Cerinic, Silvia Laura Bosello, on behalf of the SPRING Italian Registry Collaborators   +77 more
wiley   +1 more source

Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]

, 2017
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Duranti, Guglielmo, Massimiliano Sansone, Luigi Di Luigi, Roberta Ceci, Sansone, Massimiliano, Guglielmo Duranti, Paolo Sgrò, Crescioli, Clara, Clara Crescioli, Sabatini, Stefania, Borrione, Paolo, CECI GALANOS, ROBERTA, Paolo Borrione, Sgrò, Paolo, Sansone, Andrea, Stefania Sabatini, Di Luigi, Luigi, Andrea Sansone   +17 more
core   +1 more source